Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia

A Perspective

Bibliographic Data

ID15528159
AuthorsPetr Morozov (0000-0002-8537-2457, Pirogov Russian National Research Medical University, corresponding author), Roman Aleksandrovich Bekker (0000-0002-0773-3405, Ben-Gurion University of the Negev), Roman Bekker, Youri Bykov (Stavropol State Medical University)
Year2022
Volume13
Pages868751-868751
Publication date2022-04-27
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2022.868751
PMID35573354
OpenAlexW4224938371
LanguageEN
Citations received2
References cited65

Social dysfunction is one of the most debilitating aspects of schizophrenia. Treatment of this complex phenomenon, constituted by negative, cognitive, and affective symptoms, has been difficult with the available pharmacological agents, hence it represents an unmet medical need. Cariprazine, a novel, third-generation antipsychotic with a unique mechanism of action has been proven to sufficiently alleviate negative, cognitive, and affective symptoms of schizophrenia. These characteristics make this compound a valid candidate for addressing social dysfunction too. In this perspective, we argue that cariprazine can be viewed as a "socializing drug" that has the ability to improve the patient's functionality and ultimately their quality of life. Data from animal research, clinical trials, an observational study, and patient cases are provided

Perspective (graphical · Psychiatry · Psychotherapist · Schizophrenia (object-oriented programming · Child and Adolescent Psychosocial and Emotional Development · Computer Science · Medicine · Obsessive-Compulsive Spectrum Disorders · Psychology · Schizophrenia research and treatment · Artificial Intelligence

Tools

Open DOIOpen Access